84.46
+0.81%
Close of 9 Nov 2026, in CHF
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sandoz Group
Its shares trade on SIX under the ticker SDZ.SW. It has been listed since 4 October 2023. In the fiscal year to 31 December 2025, it reported revenue of $11.16bn and net income of $957.5m. At that date it held total assets of $22.03bn and shareholders' equity of $9.38bn.
Sandoz Group AG is a CH-based company operating in Pharmaceuticals industry. The company is headquartered in Rotkreuz, Zug. The company went IPO on 2023-10-04. Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The firm operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The firm serves customers worldwide.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 4 Oct 2023
Leadership
Pay as last reported
- Mr. Gilbert GhostineNon-Executive Independent Chairman of the BoardCHF 861,993
- Mr. Richard SaynorChief Executive OfficerCHF 6.8m
- Dr. Karen HuebscherNon-Executive Independent Vice Chairman of the BoardCHF 344,675
- Mr. Remco SteenbergenChief Financial Officer, since 2023CHF 9.1m
- Mr. Francisco BallesterPresident, International
- Mr. Christophe DelentaPresident, Europe
- Ms. Keren HaruviPresident, North America
- Ms. Claire D'Abreu-HaylingChief Scientific Officer
- Ms. Ingrid SollererChief Compliance Officer, Group General Counsel
- Mr. Glenn GereckeChief Manufacturing and Supply Officer
- Ms. Rebecca GunternChief Commercial Officer
- Ms. Tripti JhaChief People Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 72
- Environment
- 50
- Social
- 87
- Governance
- 79
- Direct emissions (scope 1)
- 86,200 t
- Energy emissions (scope 2)
- 129,300 t
- Value chain emissions (scope 3)
- 2,051,700 t
- Women in the workforce
- 53%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sandoz operates in two distinct businesses, Generics and Biosimilars.
- The product portfolio covers all therapeutic areas for patient treatment.
- The firm serves customers worldwide with its pharmaceutical offerings.
Weaknesses
- The company is a recent entrant having gone public in 2023.
- Specific financial metrics and revenue figures are not provided.
- Market share data relative to competitors is absent from the description.
Opportunities
- Expansion in healthcare technology industry presents new avenues.
- Growing global demand for biosimilars supports business growth.
- Developing active ingredients offers further market penetration potential.
Threats
- Regulatory changes in the pharmaceutical industry could impact operations.
- Competition from other generic and biosimilar manufacturers is intense.
- Economic fluctuations may affect worldwide customer purchasing power.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.